Thalidomide-O-amido-C6-NH2
Code | Size | Price |
---|
TAR-T39361-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T39361-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Thalidomide-O-amido-C6-NH2 (Cereblon Ligand-Linker Conjugates 11) is a Thalidomide-based synthetic E3 ligase ligand-linker conjugate, comprising of a cereblon ligand and a linker. This compound is employed in the production of PROTACs (proteolysis-targeting chimeras).
CAS:
1950635-13-8
Molecular Weight:
430.45
Purity:
0.98
SMILES:
O=C(NCCCCCCN)COC1=CC=CC=2C(=O)N(C(=O)C12)C3C(=O)NC(=O)CC3
References
Bradner J, et al. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO 2017024318 A1.